<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027781</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-16006-30005</org_study_id>
    <secondary_id>EORTC-16006-30005</secondary_id>
    <secondary_id>MAC-07</secondary_id>
    <nct_id>NCT00027781</nct_id>
  </id_info>
  <brief_title>MEN-10755 in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone Therapy</brief_title>
  <official_title>Open Label Phase II Study of MEN-10755 Administered Every 3 Weeks in Patients With Progressive Hormone Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of MEN-10755 in treating patients who have&#xD;
      progressive prostate cancer that has not responded to hormone therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the activity of MEN-10755 in patients with progressive hormone-refractory&#xD;
           adenocarcinoma of the prostate.&#xD;
&#xD;
        -  Determine the rate and duration of objective PSA response in patients treated with this&#xD;
           drug.&#xD;
&#xD;
        -  Determine the clinical response rate in patients with measurable disease treated with&#xD;
           this drug.&#xD;
&#xD;
        -  Determine the acute side effects of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Beginning within 2 weeks after the last PSA measurement, patients receive MEN-10755 IV over&#xD;
      30 minutes on day 1. Treatment repeats every 3 weeks for at least 4 courses in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients who achieve a complete or partial&#xD;
      response continue to receive additional courses. Patients who achieve stable disease may&#xD;
      receive more than 4 courses at the discretion of the investigator.&#xD;
&#xD;
      Patients are followed every 6 weeks until disease progression or initiation of a new therapy.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 18-32 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">37</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sabarubicin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed hormone-refractory adenocarcinoma of the prostate&#xD;
&#xD;
          -  Disease progression while on prior luteinizing hormone-releasing hormone (LHRH)&#xD;
             analogues or after orchiectomy and antiandrogens, given concurrently or consecutively&#xD;
&#xD;
          -  Disease progression is defined as PSA progression documented by increases in PSA&#xD;
             recorded at 2 consecutive measurements over a prior reference value&#xD;
&#xD;
               -  Interval of at least 1 week between the reference value and the first of these&#xD;
                  two PSA increases&#xD;
&#xD;
          -  Continued elevation of PSA for at least 6 weeks after discontinuation of antiandrogens&#xD;
&#xD;
          -  Last PSA value at least 5 ng/mL (Hybritech equivalent)&#xD;
&#xD;
          -  Must have serum testosterone less than 50 ng/mL and must continue on LHRH agonist&#xD;
             therapy if no prior surgical castration&#xD;
&#xD;
          -  No symptomatic brain or leptomeningeal metastatic disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT/AST no greater than 2.5 times ULN (5 times ULN if liver metastases present)&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.7 mg/dL&#xD;
&#xD;
          -  No uncontrolled hypercalcemia&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No history of severe heart disease&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No cardiac insufficiency&#xD;
&#xD;
          -  Normal cardiac function by MUGA scan and 12-lead EKG&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other prior or concurrent malignancy except basal cell or squamous cell skin cancer&#xD;
&#xD;
          -  No uncontrolled systemic nonmalignant disease or infection&#xD;
&#xD;
          -  No psychological, familial, or geographical conditions that would preclude compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior hormonal therapy except estramustine&#xD;
&#xD;
          -  No concurrent estramustine&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy (e.g., for painful bone metastases)&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent experimental drugs or investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Fiedler, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universit√§tsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>B-2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer, Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaets-Krankenhaus Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D-20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - Beilinson Campus</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital, Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Fiedler W, Tchen N, Bloch J, Fargeot P, Sorio R, Vermorken JB, Collette L, Lacombe D, Twelves C; EORTC new drug development group. A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer. Eur J Cancer. 2006 Jan;42(2):200-4. Epub 2005 Dec 7.</citation>
    <PMID>16337787</PMID>
  </results_reference>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>December 7, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 23, 2012</last_update_submitted>
  <last_update_submitted_qc>July 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

